LA JOLLA, CA - GRI Bio, Inc. (NASDAQ: GRI), a biotechnology firm focused on developing treatments for inflammatory and autoimmune diseases, announced today that it has regained compliance with Nasdaq's listing standards. Consequently, the previously scheduled hearing with the Nasdaq Hearings Panel has been canceled.
On July 2, 2024, GRI Bio received formal notification from Nasdaq confirming the company's adherence to all applicable requirements for continued listing on the Nasdaq Capital Market. This development follows a period of uncertainty regarding the company's listing status.
Marc Hertz, CEO of GRI Bio, expressed his enthusiasm about the company's reinstatement and emphasized the team's commitment to advancing their pipeline of Natural Killer T (NKT) cell modulators.
"We are very excited about this development and look forward to focusing our efforts on our core business—developing novel product candidates for the treatment of inflammatory, fibrotic, and autoimmune diseases," said Hertz.
GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for idiopathic pulmonary fibrosis, a condition with a significant need for new treatments.
The company is also working on novel type 2 NKT agonists for systemic lupus erythematosus and maintains a library of over 500 proprietary compounds to fuel future pipeline growth.
While the press release contains forward-looking statements regarding the development and potential benefits of GRI Bio's product candidates, these statements are based on current beliefs and expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. The company's future results may differ from these forward-looking statements.
The information in this article is based on a press release statement from GRI Bio, Inc. and has not been independently verified. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. GRI Bio does not undertake any obligation to update these statements unless required by law.
In other recent news, GRI Bio, Inc., a biotechnology firm, has been making significant strides in its research and development efforts. The company reported positive preclinical data for its lead drug candidate, GRI-0621, an IPF treatment.
GRI-0621 demonstrated potential in reducing inflammation and fibrosis in the lungs, with interim data from a Phase 2a clinical trial expected in Q3 2024 and topline results anticipated in Q4 2024.
The company has also announced a public offering that includes over 2 million shares of common stock and Series C warrants, expected to generate gross proceeds of about $4 million. This move is intended to fund product candidate development, working capital, and general corporate purposes.
GRI Bio has initiated a 1-for-13 reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement, reducing the total outstanding shares from approximately 6.6 million to about 508,091 shares.
In addition, GRI Bio reported positive preclinical data for its type 2 Natural Killer T (NKT) cell activators, GRI-0803 and GRI-0124, in treating systemic lupus erythematosus. An Investigational New Drug application for GRI-0803 is planned for the second half of 2024.
Furthermore, the company has been granted patents by the Korean Intellectual Property Office and the Canadian Intellectual Property Office, which strengthens its global intellectual property portfolio. These recent developments highlight GRI Bio's ongoing efforts in advancing its research and development initiatives.
InvestingPro Insights
Amidst the recent positive news of GRI Bio regaining compliance with Nasdaq's listing standards, investors might be looking for additional context on the company's financial health and market performance. According to InvestingPro data, GRI Bio has a notably small market capitalization of only $0.46 million USD. This size reflects the company's status as a high-risk, potentially high-reward investment typical of early-stage biotech companies.
InvestingPro Tips indicate that GRI Bio holds more cash than debt on its balance sheet, which is a positive sign for the company's financial stability. However, the stock has experienced significant volatility, with a one-month price total return as of the same period showing a steep decline of -56.62%. Additionally, the stock is in oversold territory according to the Relative Strength Index (RSI), which could suggest a potential rebound or at least attract the attention of value investors looking for an entry point.
While GRI Bio's advancements in its lead program and pipeline are promising, the company's valuation implies a poor free cash flow yield, and it has not been profitable over the last twelve months. For investors considering GRI Bio as part of their portfolio, it's important to weigh these financial metrics against the company's scientific potential and recent regulatory milestones. For further insights, there are additional InvestingPro Tips available, which can be accessed with a subscription. Use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, providing a more comprehensive investment analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.